Physician profile
Doris A Trauner
NPI 1124051420
$14,786.73
in general payments reported to CMS, 2019-2025
12 companies · $594 in 2025
The $594 reported for 2025 was more than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $441 · 2020: $259 · 2021: $4,978 · 2022: $292 · 2023: $7,873 · 2024: $350 · 2025: $594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $6,084 · Travel and Lodging: $1,611 · Food and Beverage: $1,122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $6,084.00 |
| Travel and Lodging | $1,610.56 |
| Food and Beverage | $1,122.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $12,695.09 | 2021-2023 | Procysbi |
| Amgen INC. | $572.46 | 2025 | Procysbi |
| Jazz Pharmaceuticals INC. | $435.86 | 2022-2024 | |
| Sunovion Pharmaceuticals INC. | $407.40 | 2019-2020 | |
| Neurelis, INC. | $230.58 | 2020-2024 | Valtoco |
| Biomarin Pharmaceutical INC. | $107.17 | 2019-2021 | |
| Aquestive Therapeutics, INC. | $94.42 | 2020 | |
| Immedica Pharma US, INC. | $85.34 | 2023 | |
| Eisai INC. | $51.86 | 2019 | |
| Greenwich Biosciences, INC. | $51.23 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $33.64 | 2019-2020 | |
| Aucta Pharmaceuticals, INC. | $21.68 | 2025 | Motpoly Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Doris Trauner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.